Regencell bioscience's investigational liquid-formula rgc-cov19tm shows effectiveness through its enrolled patients in eliminating mild to moderate covid-19 symptoms within the 6-day treatment period in its earth efficacy trial

Hong kong--(business wire)---- $rgc #adhd--regencell bioscience holdings limited (nasdaq: rgc) (“regencell” or the “company”) today announced the results from an analysis of a total of 37 individuals enrolled in its evaluation and assessment of rgc-cov19tm tcm through a holistic approach (“earth”) efficacy trial conducted by regencell bioscience asia limited (“regencell asia”) of its novel covid-19 oral tcm candidate rgc-cov19tm (regencell bioscience (rgca-cv01) liquid formulation). the results have yet to be
RGC Ratings Summary
RGC Quant Ranking